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OBJECTIVES: Suboptimally treated postoperative pain is
common and is a risk factor for developing chronic pain. 
Additionally, improving postoperative pain relief may improve
patient-reported outcomes such as satisfaction with care. The
purpose of this study was to assess patient satisfaction with post-
operative pain relief among persons who underwent unilateral
total knee arthroplasty. METHODS: Participants in the intent-
to-treat population were randomly assigned to controlled-release
oxycodone (CRO, n = 125) or placebo (Pla, n = 119) plus usual
care on postoperative day two. Both groups were allowed sup-
plemental analgesics as needed. Outcomes assessed in this analy-
sis at baseline and overall were pain relief and impact of pain on
daily functions using the Brief Pain Inventory (BPI; an objective
pain outcome measure) and two items related to satisfaction with
postoperative pain care, speciﬁcally, “How satisﬁed or dissatis-
ﬁed are you with the relief you experienced from your post-
surgery pain?” and “Overall how pleased have you been with
the current care you have received for post-surgery pain?”
RESULTS: Patients on CRO compared to Pla reported greater
perceived amount of pain relief from study medications (p =
0.007), with satisfaction of current care (p = 0.069) trending
towards signiﬁcance. In addition, 85.8% (CRO) and 72.0% (Pla;
p = 0.033) would recommend the care they received, including
pain management. Questions about satisfaction with pain man-
agement were positively and signiﬁcantly associated with the
Brief Pain Inventory pain relief item (r = 0.47 and 0.38, respec-
tively). CONCLUSIONS: Patients who received CRO were more
satisﬁed with their pain relief and were more likely to recom-
mend their pain care to someone else.
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OBJECTIVE: This was a retrospective claims study in a managed
care population. Selected outcomes were compared in newly-
diagnosed overactive bladder (OAB) cases and controls.
METHODS: Insurance claims data from a southeastern US
health plan totaling approximately 4.4 million members were
utilized. All patients were ≥18 years of age and had continuous
insurance eligibility for one year pre- and ≥1 year post-
enrollment date. The two year enrollment period for OAB
patients was between January 1, 2001 and December 31, 2002.
Newly-diagnosed OAB patients had ≥2 medical visits related to
OAB on separate dates during the enrollment period but not a
medical visit related to OAB in the one year pre-enrollment
period. Non-OAB controls had no medical visit related to OAB
over the period of continuous eligibility. Cases were matched to
controls utilizing a propensity score approach. All medical and
pharmacy insurance encounter data (claims) were collected for
one year pre-enrollment and ≥1 year post-enrollment for both
groups. RESULTS: Among OAB cases, 1087/4640 (23%)
received ≥1 OAB drug over the observation period; 93% dis-
continued treatment. Median treatment duration was 30 days.
Compared to non-OAB controls, OAB cases were signiﬁcantly
associated with: skin infections at rates 57% higher, urinary tract
infection (UTI) at rates 3.6 times higher, and new onset depres-
sion at rates 55% higher. CONCLUSION: Patients with OAB
were associated with higher rates of skin infection, UTI, and
new-onset depression compared to non-OAB cases. Evaluation
of effect of OAB treatment on these events was not feasible given
the low median treatment time. These events are likely to have
great quality of life impact as well as signiﬁcant health care
resource use, including outpatient visits and pharmacological
intervention.
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OBJECTIVES: To determine if costs savings from a substitution
of darpapoetin for epoetin were as predicted by an economic
model. METHODS: Our hospital, part of a National purchas-
ing consortium, was convinced to switch all patients receiving
either thrice weekly or weekly epoeitin, in connection with either
chemotherapy of chronic renal disease, to once weekly dar-
bapoeitin. An economic model showed that under the assump-
tions provided, combined with a 22% rebate of cost from the
manufacturer, that total costs would be lower with darbapoetin.
Clinical literature was reviewed showing similar efﬁcacy of the
two agents. RESULTS: After implementing the switch, the costs
of making the subsitution were much higher than the beneﬁts.
Use and acquisition costs of darbapoetin was signiﬁcantly greater
than the prior year and then were predicted using the economic
model. Signiﬁcant ﬁndings were; a) demonstrated lack of clini-
cal equivalence lead to physicians prescribing 2.8 times the rec-
ommended dose of darbapoetin and; b) paying for a week’s
worth of therapy for patients who would only have received an
average of 1.3 doses of epoeitin based on their duration of stay
in the hospital. A revised model based on more realistic assump-
tions showed a net cost would result if the substitution were con-
tinued. CONCLUSION: Despite the results predicted by the
economic model, without restrictions on the amount of drug to
be ordered, the total costs to our health care system turned out
to be much greater after the substitution.
PUK3
AN ECONOMIC MODEL OF OVERACTIVE BLADDER
TREATMENT PERSISTENCE:TOLTERODINE ER COMPARED TO
OXYBUTYNIN ER
Subedi P1, Jumadilova Z2, Perfetto EM3
1University of Maryland School of Pharmacy, Baltimore, MD, USA;
2Pﬁzer, Inc, New York, NY, USA; 3The Weinberg Group, Inc,
Washington, DC, USA
OBJECTIVE: Successful treatment of overactive bladder (OAB)
reduces the occurrence of OAB symptoms and associated condi-
tions and may reduce total health care costs. The objective of
this study was to compare treatment discontinuation and one-
year health care costs for OAB patients starting treatment with
extended-release tolterodine (TOL) versus extended-release oxy-
butynin (OXY). METHODS: A cost-minimization model was
developed from the payer perspective. A cohort of OAB patients
newly treated with TOL (n = 15,394) or OXY (n = 7934) was
